Related Experiment Video
Updated: Jul 10, 2026
08:32
Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Propranolol preparations on the Belgian market: a comparative study.
K De Braekeleer1, C Fierens, J Corthout
1Service de Contrôle des Médicaments - Dienst Geneesmiddelen-onderzoek, rue Stévin, 137, B-1000 Bruxelles.
Journal De Pharmacie De Belgique
|October 25, 2007
Summary
Propranolol tablets and capsules were tested for quality and found to be pharmaceutically equivalent. This ensures that different propranolol formulations meet rigorous standards for patient safety and efficacy.
Area of Science:
- Pharmaceutical Sciences
- Drug Quality Control
Background:
- Propranolol is a widely used beta-blocker medication.
- Ensuring pharmaceutical equivalence of different drug formulations is crucial for therapeutic consistency.
Purpose of the Study:
- To evaluate the pharmaceutical equivalence of immediate-release propranolol tablets and prolonged-release capsules.
- To assess drug product quality based on established pharmacopeial standards.
Main Methods:
- In vitro dissolution testing was performed on propranolol preparations.
- Assay testing was conducted using validated analytical methods.
- Evaluations followed guidelines from the European network of Official Medicines Control Laboratories (OMCLs).
Main Results:
- All tested propranolol tablets and capsules met predefined quality requirements.
- The products complied with specifications outlined in the European, British, and US Pharmacopoeias.
- The examined propranolol formulations demonstrated consistent quality.
Conclusions:
- Immediate-release propranolol tablets and prolonged-release capsules are pharmaceutically equivalent.
- The evaluated propranolol products meet stringent quality standards, ensuring interchangeability.
- This study supports the reliable use of various propranolol formulations in clinical practice.
Related Concept Videos
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:28Antihypertensive Drugs: Types of β-Blockers
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...